Cipla’s Q2FY25 Results
Cipla’s revenue grew over 5% YoY
- 04 Nov 2024
- Cipla reported 6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended Sept (Q2FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.6%.
- Its expenses for the quarter were up by 4% QoQ and 3.7% YoY.
- The net profit grew 11% QoQ and 13% YoY.
- The earnings per share (EPS) of Cipla stood at 16.1 during Q2FY25.
Cipla’s Financial Statements for Q2FY25:
| (₹ crores) | Q2FY24 | Q1FY25 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total income | 6,854 | 6,854 | 7,242 | 6% | 5.6% |
Total expenses | 5,260 | 5,243 | 5,453 | 4% | 3.7% |
Profit before tax | 1,594 | 1,611 | 1,789 | 11% | 12.2% |
Tax | 438 | 435 | 483 | 11% | 10.2% |
Profit after tax | 1,155 | 1,175 | 1,305 | 11% | 13.0% |
Earnings per share | 14.0 | 14.6 | 16.1 |
Financials:
H1 2024-2025 Results Summary
- Business grew 5% YoY, with strong growth in Chronic therapies but slower Acute category growth.
- Revenue growth at 22% as North Africa merges with SAGA into One Africa.
- R&D investments stand at ₹385 Cr or 5.5% of sales, higher by 2% YoY driven by product filings and developmental efforts.
- Net cash position of ₹7,950 Cr. Debt primarily includes lease liabilities and working capital requirements.
Management Commentary:
Umang Vohra, MD and Global CEO, Cipla Ltd.
- Q2 FY25 revenue grew 9% YoY with record EBITDA margin at 26.7%.
- One-India business saw impact from seasonal shifts, though chronic therapies outperformed.
- Consumer Health grew 21% YoY.
- US business revenue reached $237 million, emphasizing differentiated portfolio success.
- South Africa grew 22% YoY, led by Private Market.
- Emerging Markets & Europe reported an 18% YoY growth.
- Strategic focus on market expansion, flagship brands, pipeline investments, and regulatory resolutions.
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
